METSERA INC (MTSR) Stock Price & Overview
NASDAQ:MTSR • US59267L1070
Current stock price
The current stock price of MTSR is 70.5 USD. Today MTSR is down by -0.35%. In the past month the price increased by 33.37%.
MTSR Key Statistics
- Market Cap
- 7.429B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.71
- Dividend Yield
- N/A
MTSR Stock Performance
MTSR Stock Chart
MTSR Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to MTSR.
MTSR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MTSR. No worries on liquidiy or solvency for MTSR as it has an excellent financial health rating, but there are worries on the profitability.
MTSR Earnings
MTSR Forecast & Estimates
8 analysts have analysed MTSR and the average price target is 54.57 USD. This implies a price decrease of -22.6% is expected in the next year compared to the current price of 70.5.
MTSR Groups
Sector & Classification
MTSR Financial Highlights
Over the last trailing twelve months MTSR reported a non-GAAP Earnings per Share(EPS) of -3.71. The EPS decreased by -342.97% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -55.41% | ||
| ROE | -78.9% | ||
| Debt/Equity | 0 |
MTSR Ownership
MTSR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.11 | 370.255B | ||
| AMGN | AMGEN INC | 15.28 | 188.011B | ||
| GILD | GILEAD SCIENCES INC | 15.19 | 166.661B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.34 | 110.013B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.78 | 77.991B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.53 | 42.088B | ||
| INSM | INSMED INC | N/A | 31.319B | ||
| BIIB | BIOGEN INC | 11.43 | 26.98B | ||
| NTRA | NATERA INC | N/A | 25.887B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.5 | 22.916B | ||
| MRNA | MODERNA INC | N/A | 19.573B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.333B | ||
| INCY | INCYTE CORP | 11.79 | 17.971B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MTSR
Company Profile
Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. The company is headquartered in New York City, New York and currently employs 74 full-time employees. The company went IPO on 2025-01-31. The firm uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization, or HALO, half-life extending platform and its MOMENTUM oral NuSH analog peptide delivery platform to deliver highly differentiated product candidates. Its product pipeline includes MET-097i, MET-233i / MET-233i + MET-097i and MET-224o. MET-097i, its advanced product candidate, is a fully biased, monthly, subcutaneously injectable ultra-long acting GLP-1 RA. MET-233i is a subcutaneously injectable ultra-long-acting amylin analog, with enhanced solubility and miscibility with its other NuSH analog peptides. MET-224o is an oral, fully biased ultra-long acting GLP-1 RA. The firm's pipeline also includes MET-002o, MET-AMYo, MET-034i, MET-067i and MET-PYYi.
Company Info
IPO: 2025-01-31
METSERA INC
3 World Trade Center, 175 Greenwich Street
New York City NEW YORK US
Employees: 74
Phone: 12127846595
METSERA INC / MTSR FAQ
What does METSERA INC do?
Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. The company is headquartered in New York City, New York and currently employs 74 full-time employees. The company went IPO on 2025-01-31. The firm uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization, or HALO, half-life extending platform and its MOMENTUM oral NuSH analog peptide delivery platform to deliver highly differentiated product candidates. Its product pipeline includes MET-097i, MET-233i / MET-233i + MET-097i and MET-224o. MET-097i, its advanced product candidate, is a fully biased, monthly, subcutaneously injectable ultra-long acting GLP-1 RA. MET-233i is a subcutaneously injectable ultra-long-acting amylin analog, with enhanced solubility and miscibility with its other NuSH analog peptides. MET-224o is an oral, fully biased ultra-long acting GLP-1 RA. The firm's pipeline also includes MET-002o, MET-AMYo, MET-034i, MET-067i and MET-PYYi.
What is the current price of MTSR stock?
The current stock price of MTSR is 70.5 USD. The price decreased by -0.35% in the last trading session.
What is the dividend status of METSERA INC?
MTSR does not pay a dividend.
What is the ChartMill rating of METSERA INC stock?
MTSR has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for MTSR stock?
8 analysts have analysed MTSR and the average price target is 54.57 USD. This implies a price decrease of -22.6% is expected in the next year compared to the current price of 70.5.
When does METSERA INC (MTSR) report earnings?
METSERA INC (MTSR) will report earnings on 2026-03-24.
Who owns METSERA INC?
You can find the ownership structure of METSERA INC (MTSR) on the Ownership tab.